Its approval was based on the ADMIRAL trial, a randomized phase III trial where patients with relapsed or refractory FLT3-mutated AML were randomly assigned to receive either gilteritinib (120 mg per day) or salvage chemotherapy according to local investigators’ choice. Here, FLT3 is linked to acute myeloid leukemia.